Trial Information

Lung cancer is the leading cause of cancer death in Taiwan and world wild. Although there
were progresses in the diagnosis and treatment of lung cancer, the incidence and mortality
rate of lung cancer increased in recent years. In many cases, lung cancer is not diagnosed
and treated until cancer cells have already invaded surrounding tissues and metastasized
throughout the body. Only 15% of lung cancer patients were operable at presentation and
about half of them had long term survival. The remaining almost died of metastatic disease.
Detecting lung cancers when they are at their earliest stages, and identify cancers with
metastatic potential will have a higher probability of truly curing the disease. Molecules
that are expressed uniquely or at high level by tumor cells in comparison to normal tissues
and that may be secreted into accessible fluids such as blood, urine, or sputum may be
useful as lung cancer biomarkers. By using tools in SAGE Genie of Cancer Genome Anatomy
Project (CGAP), we identified a secreted protein, SERPIN D1, as an overexpressed gene in
non-small cell lung cancer as compared with normal lung and any other normal tissue. In an
established panel of human lung adenocarcinoma cell lines with different invasive activities
(CL1–0 cells and its sublines CL1–1, and CL1–5, in ascending order of activity), we detected
that the expression of SERPIN D1 was higher in CL1-5 than in CL1-0 and CL1-1. According to
our preliminary results, we hypothesize that SERPIN D1 may play a role in lung cancer
invasion and metastasis and may serve as a serum biomarker for prognosis stratification. For
this study, we are going to evaluate the potential correlation between SERPIN D1 expression
in clinical specimen (including surgical specimen and blood sample) and lung cancer
metastasis.